Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma

Oncogene

Volumn 33, Issue 28, 2014, Pages 3748-3752

  Tallet, A ^a,b   Nault, J C ^a,b   Renier, A ^a,b   Hysi, I ^c   Galateau Salle F ^d,e   Cazes, A ^f   Copin, M C ^g   Hofman, P ^h   Andujar, P ^i,j   Le Pimpec Barthes, F ^a,b,f   Zucman Rossi, J ^a,b   Jaurand, M C ^a,b   Jean, D ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e Biology and Innovative Therapeutics for Ovarian Cancers Group   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g UNIV LILLE   (France)

^h PASTEUR HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^j INSERM U955   (France)

more..

Author keywords

asbestos; mesothelioma; mutation; telomerase reverse transcriptase; telomere; thoracic neoplasm

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TELOMERASE;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE DOSAGE; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRAIT; HUMAN; MESOTHELIUM CELL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MUTATION; PLEURAL NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TELOMERASE;

EID: 84904245633     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.351     Document Type: Article

References (30)

1. Huang SX, Jaurand MC, Kamp DW, Whysner J, Hei TK. Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B 2011; 14: 179-245.
2. Jasani B, Gibbs A. Mesothelioma not associated with asbestos exposure. Arch Pathol Lab Med 2012; 136: 262-267.
3. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43: 1022-1025.
4. Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand MC. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 2012; 136: 277-293.
5. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43: 668-672.
6. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010; 11: 319-330.
7. Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A et al. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2008; 14: 4134-4140.
8. Au AY, Hackl T, Yeager TR, Cohen SB, Pass HI, Harris CC et al. Telomerase activity in pleural malignant mesotheliomas. Lung Cancer 2011; 73: 283-288.
9. Dhaene K, Hubner R, Kumar-Singh S, Weyn B, Van Marck E. Telomerase activity in human pleural mesothelioma. Thorax 1998; 53: 915-918. (Pubitemid 28494328)
10. Kumaki F, Kawai T, Churg A, Galateau-Salle FB, Hasleton P, Henderson D et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 2002; 26: 365-370. (Pubitemid 34184461)
11. Gladych M, Wojtyla A, Rubis B. Human telomerase expression regulation. Biochem Cell Biol 2011; 89: 359-376.
12. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959-961.
13. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957-959.
14. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr. LA et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110: 6021-6026.
15. Zeng L, Buard A, Monnet I, Boutin C, Fleury J, Saint-Etienne L et al. In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer 1993; 55: 515-520. (Pubitemid 23300607)
16. Jean D, Thomas E, Manie E, Renier A, de Reynies A, Lecomte C et al. Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol 2011; 178: 881-894.
17. Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331.
18. Cao Y, Bryan TM, Reddel RR. Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci 2008; 99: 1092-1099. (Pubitemid 351676619)
19. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012; 498: 135-146.
20. Ramael M, Van den Bossche J, Buysse C, Deblier I, Segers K, Van Marck E. Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura. Histol Histopathol 1995; 10: 639-643.
21. Wang NS. Mesothelial cells in situ. In: Chrétien JB J, Hirsch A (eds). The Pleura in Health and Disease. Marcel Dekker: New York, NY, USA, 1985, pp 23-42.
22. Mutsaers SE. Mesothelial cells: their structure, function and role in serosal repair. Respirology 2002; 7: 171-191.
23. Shen XH, Xu SJ, Jin CY, Ding F, Zhou YC, Fu GS. Interleukin-8 prevents oxidative stress-induced human endothelial cell senescence via telomerase activation. Int Immunopharmacol 2013; 16: 261-267.
24. Ganem NJ, Pellman D. Linking abnormal mitosis to the acquisition of DNA damage. J Cell Biol 2012; 199: 871-881.
25. Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L et al. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 2005; 4: 1862-1869. (Pubitemid 41827334)
26. Andujar P, Wang J, Descatha A, Galateau-Salle F, Abd-Alsamad I, Billon-Galland MA et al. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer 2010; 67: 23-30.
27. Andujar P, Pairon JC, Renier A, Descatha A, Hysi I, Abd-Alsamad I et al. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis 2013; 28: 321-323.
28. Larsson LG. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 2011; 21: 367-376.
29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2012; 144: 646-674.
30. Bazarov AV, Van Sluis M, Hines WC, Bassett E, Beliveau A, Campeau E et al. p16(INK4a)-mediated suppression of telomerase in normal and malignant human breast cells. Aging Cell 2010; 9: 736-746.